Skip to Content

New Drug Approvals Archive - December 2009

December 2009

Zegerid OTC (omeprazole and sodium bicarbonate) Capsules

Date of Approval: December 1, 2009
Company: Merck & Co. and Santarus Inc.
Treatment for: Heartburn

Zegerid OTC (omeprazole and sodium bicarbonate) is an over-the-counter version of the prescription heartburn drug Zegerid.

Read more: Zegerid OTC (omeprazole and sodium bicarbonate) FDA Approval History

Kalbitor (ecallantide) Injection - formerly DX-88

Date of Approval: December 1, 2009
Company: Dyax Corp.
Treatment for: Angioedema

Kalbitor (ecallantide) is plasma kallikrein inhibitor indicated for treatment of acute attacks of hereditary angioedema in patients 16 years of age and older.

Read more: Kalbitor (ecallantide) FDA Approval History

Zyprexa (olanzapine)

Patient Population Altered: December 4, 2009

Wilate (von Willebrand Factor/Coagulation Factor VIII Complex (Human)) Injection

Date of Approval: December 4, 2009
Company: Octapharma USA
Treatment for: von Willebrand's Disease

Wilate is a von Willebrand Factor/Coagulation Factor VIII Complex (Human) indicated for the treatment of spontaneous and trauma-induced bleeding episodes in patients with severe von Willebrand disease (VWD).

Read more: Wilate (von Willebrand Factor/Coagulation Factor VIII Complex (Human)) FDA Approval History

Zyprexa Relprevv (olanzapine) for Extended Release Injectable Suspension

Date of Approval: December 11, 2009
Company: Lilly
Treatment for: Schizophrenia

Zyprexa Relprevv (olanzapine) is a long-acting atypical antipsychotic for intramuscular injection indicated for the treatment of schizophrenia.

Read more: Zyprexa Relprevv (olanzapine) FDA Approval History

Fluzone (influenza virus vaccine, inactivated)

New Formulation Approved: December 23, 2009

New Drug Approvals Archive